Corporate ProfileNantHealth is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth‘s unique systems-based approach to personalized healthcare integrates novel diagnostics with large-scale, biometric and phenotypic data to track patient outcomes and deliver precision medicine. In addition, NantHealth’s adaptive learning system, CLINICS, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time.
Stock Quote NH (Common Stock) $0.67 - 0.01 (0.00%)
Today's Open$0.67
Previous Close$0.67
Data as of 02/22/19 2:02 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NH.O.  Currently trading at $0.67 with a 52 week high of $3.77 and a 52 week low of $0.48.
Recent News

February 14, 2019

NantHealth® and NantOmics to Reveal New Research Demonstrating Importance of Examining RNA Expression and Individual Biomarkers in Cancer Testing

Findings to be presented at the 2019 American Society of Clinical Oncology’s Genitourinary Cancers Symposium SAN FRANCISCO & CULVER CITY, Calif.--(BUSINESS WIRE)--Feb. 14, 2019-- Scientific teams from NantHealth (NASDAQ: NH) and NantOmics will present two posters at the American Society of Clinical Oncology’s (ASCO) Genitourinary Cancers Symposium this week. The two companies, respective leaders in molecular profiling research and g...

Read More >

February 12, 2019

NantHealth® Debuts Multiple Connected Care Initiatives at HIMSS

Collaboration with Leading Kidney Care Vendors, Intelligent Health and Connected Care Showcased CULVER CITY, Calif. & ORLANDO, Fla.--(BUSINESS WIRE)--Feb. 12, 2019-- NantHealth, Inc. (NASDAQ: NH), a leader in connected care solutions, will unveil a series of new initiatives designed to improve patient outcomes and provider satisfaction at the 2019 Healthcare Information and Management Systems Society (HIMSS) Annual Conference and Exhibition ...

Read More >

January 04, 2019

NantCell Announces New Celgene Investment

Immunotherapy Company Will Present Findings at the JP Morgan Healthcare Conference in San Francisco on January 7thSecond Round Crossover Funding Brings Celgene's Investment to $105M in NantCell Valued at $4 BillionCurrently Enrolling Patients in Advanced Stage Trials in 15 Indications for Registration IntentDeep Pipeline Of 28 Unique Molecules With 14 First in Human Studies in Over 1,000 Patients to DateLos Angeles, CA, January 4, 2019 – NantCell and its founder Dr. Patrick Soon-Shiong announced...

Read More >

Upcoming Events
There are currently no events scheduled.